New epilepsy drug filed for approval

GlaxoSmithKline and Valeant Pharmaceuticals have submitted a marketing authorisation application to the European Medicines Agency for their epilepsy treatment, retigabine.

by
Retigabine is thought to cause a hyperpolarising shift in the neuronal potassium current and thereby reduce the excitability of neuronal cells.
Retigabine is thought to cause a hyperpolarising shift in the neuronal potassium current and thereby reduce the excitability of neuronal cells.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package